Svetinorm
- Category
- Bioregulators
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
Svetinorm is a liver-derived bioregulator peptide marketed to aid liver regeneration in hepatitis, chemo recovery, and general liver strain. Benefits remain unproven, despite an internal report describing human outcomes. It is not a substitute for medical treatment, and mild allergy to the material is possible. It is not FDA-approved; it is sold internationally as a dietary supplement, and unregulated products sold online vary in quality.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Svetinorm is a natural peptide bioregulator containing peptide complex A-7, derived from liver tissue of young calves. Developed by Professor Vladimir Khavinson, it belongs to the Cytomaxes class and targets the liver, where it is designed to restore hepatocyte metabolism and normalize liver cell functional activity. The peptides have a molecular weight up to 10,000 Da and possess tissue-specific action on liver cells.
A clinical study conducted at the St. Petersburg Institute of Bioregulation and Gerontology compared 47 patients with chronic hepatitis or after chemotherapy for cancer (ages 35-68, disease duration 3-10 years) receiving Svetinorm plus standard therapy against 38 controls on standard therapy alone. Most patients reported elimination of fatigue, improved appetite and working capacity, and 53% experienced considerable decrease in pain syndrome. Biochemical markers including bilirubin, ALT, and immunoglobulin levels showed improvement.
Svetinorm is positioned as a hepatoprotective supplement for chronic liver conditions, post-chemotherapy recovery, chronic intoxication, and age-related liver function decline. It is manufactured in capsule form and is available as a dietary supplement.
How it works in the body
A bioregulator peptide complex derived from liver tissue that regulates hepatocyte gene expression. It promotes the synthesis of liver-specific proteins involved in detoxification, bile production, and metabolic processing, supporting liver regeneration and function.
Research overview
Svetinorm has a formal clinical study report from the St. Petersburg Institute covering 47 treatment patients and 38 controls. The study included two groups: chronic persisting hepatitis patients (34 total, ages 35-56) and post-chemotherapy oncological patients (13 total, ages 53-68). Treatment duration was 15-20 days at 2 capsules twice daily. The report describes symptom improvement and biochemical changes from baseline; it does not establish statistically significant superiority over standard treatment. The study concluded with evidence of hepatoprotective properties and recommended Svetinorm for complex treatment of acute and chronic liver disorders. Additional supporting literature comes from Jay Campbell's health education platform describing the mechanism as enhancing cellular resilience and regeneration.
Who researches Svetinorm?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching liver health
Studied for hepatoprotective effects or liver function support.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(2)
Rated by level of concern
Allergic reaction to bovine liver-derived peptides
LowClass/mechanism reasoning only; no FDA-approved labeling and no adverse-event database entry exists for Svetinorm
Not a substitute for medical liver treatment
HighStandard hepatology practice (AASLD-IDSA HCV guidance; EASL clinical practice guidelines); no regulatory approval for Svetinorm as a therapy
Interaction summary(7)
Rated by direction with this peptide
Direct-acting antivirals / interferon for hepatitis B or C
CautionModerateNo pharmacologic interaction is documented or studied. The risk is substitution, not chemistry: using a bioregulator instead of, or as a reason to delay, curative antiviral therapy is the main plausible harm pathway in chronic hepatitis. Severity is set at Moderate to reflect the magnitude of that missed-treatment harm, not any demonstrated drug-drug effect.
AASLD-IDSA / EASL hepatitis treatment guidance; no interaction study exists
Cytotoxic chemotherapy (e.g., methotrexate, anthracyclines, platinum agents)
CautionTheoreticalA preparation marketed as promoting hepatocyte regeneration has never been tested for effects on chemotherapy efficacy, hepatic drug clearance, or tumor biology, so co-use during active oncology treatment should be cleared with the treating oncologist.
No published interaction data; mechanism-based inference only
Hepatotoxic drugs (acetaminophen, isoniazid, amiodarone, high-dose statins)
CautionTheoreticalAnimal data on related liver peptide complexes suggest antioxidant/hepatoprotective effects, but nothing establishes this in humans, and any perceived protection could mask rising transaminases and delay recognition of real drug-induced liver injury. Listed as Caution rather than Protective for that reason.
PMID 32362099 (animal hepatoprotection, related compounds); masking risk is clinical inference
Alcohol
CautionModerateNot a pharmacologic interaction. Continued alcohol use is the dominant driver of progression in most liver disease and is not offset by any supplement; a hepatoprotective claim should never be treated as license to keep drinking.
Standard hepatology practice
Narrow-therapeutic-index drugs cleared hepatically (warfarin, tacrolimus, phenytoin)
CautionTheoreticalEntirely conditional: if the claimed enhancement of hepatocyte synthetic and detoxification capacity were real, hepatic clearance and clotting-factor synthesis could shift enough to change INR or trough levels. Unstudied in humans, so monitor rather than assume no effect — but note there is no evidence the underlying effect occurs at all.
Mechanism-based extrapolation; no human PK data
Immunosuppressants after liver transplant
CautionTheoreticalThe related liver peptide literature reports immunomodulatory effects in animal models, which is an unwanted and unquantified variable in a patient whose graft depends on controlled immunosuppression. No human immunologic data exist.
PMID 32362099 (immune status normalization reported in animal models of related peptides)
Ursodeoxycholic acid
NeutralLowNo documented or plausible interaction. UDCA has real trial evidence in cholestatic liver disease and should be dosed on its own merits, with the peptide adding no demonstrated benefit on top.
No interaction data located
Known risks(2)
Allergic reaction to bovine liver-derived peptides
LowNo serious adverse events reported in the clinical study.
Not a substitute for medical liver treatment
ImportantSvetinorm is a dietary supplement and should not replace medical treatment for serious liver conditions including viral hepatitis, cirrhosis, or liver failure.
Drug interactions(2)
Hepatotoxic medications (acetaminophen, statins, etc.)
Theoretical benefit as hepatoprotective; no documented interaction
Antiviral medications for hepatitis
Used concurrently in Russian clinical practice; no documented antagonism
Research & benefits
Evidence base
- Evidence Level
- Limited Evidence
- Total Studies
- 3
- Human Studies
- 85
Svetinorm has a formal clinical study from the Khavinson Institute testing 47 patients against 38 controls, which is among the better-documented bioregulator studies. Results showed hepatoprotective effects in chronic hepatitis and post-chemotherapy patients with improvements in both subjective symptoms and biochemical markers. However, the study was open-label, conducted at a single center, and has not been replicated outside Russia.
Researched for(4)
Rated by confidence in the evidence
Hepatoprotective effects in chronic hepatitis
SpeculativeAn internal human report studied Svetinorm; benefit remains uncertain.
PMID 32362099 (Adv Gerontol 2020;33(1):159-164, review of polypeptide liver complex Ventvil + tetrapeptide KEDA/Livagen); it does not study Svetinorm
Improved liver function markers (bilirubin, ALT reduction)
SpeculativeAn internal human report includes bilirubin and ALT measurements; efficacy remains unconfirmed.
PMID 32362099 (animal/in vitro, general liver-function language only); no trial registration identified for Svetinorm
Post-chemotherapy liver recovery support
SpeculativeAn internal report includes 13 post-chemotherapy patients; benefit remains uncertain.
No primary source located; indirect extrapolation from PMID 32362099 animal hepatitis/fibrosis models
Reduced fatigue and improved appetite in liver disease patients
SpeculativeUncontrolled observational reports only, no peer-reviewed or blinded human data exist.
No peer-reviewed human trial identified; claim not supported by PMID 32362099
Benefits(4)
Hepatoprotective effects in chronic hepatitis
Khavinson Institute clinical study (47 patients + 38 controls)
Improved liver function markers (bilirubin, ALT reduction)
Khavinson Institute clinical study (Oct 2003 - Jan 2004)
Post-chemotherapy liver recovery support
Khavinson Institute clinical study (13 oncological patients)
Reduced fatigue and improved appetite in liver disease patients
Khavinson Institute clinical study subjective outcomes
Key studies(1)
Clinical study of the biologically active peptide bioregulator Svetinorm
Open-label clinical studyn=47 treatment + n=38 control15-20 daysKhavinson VKh et al.
St. Petersburg Institute of Bioregulation and Gerontology (internal report)
2004
Hepatoprotective effects demonstrated in chronic hepatitis and post-chemotherapy patients. Most patients showed improved symptoms (fatigue, appetite, pain) and biochemical markers (bilirubin, ALT, immunoglobulin levels).
Regulation & availability
Why researchers look at it
Svetinorm targets liver cell metabolism with organ-specific peptides from young calf liver. Its clinical study in chronic hepatitis and post-chemotherapy patients showed improved liver markers, making it one of the better-documented Khavinson bioregulators for liver support.
- Estimated cost
- $30-60/mo (capsules)
- FDA status
- Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
- WADA status
- Not listed on WADA Prohibited List; not evaluated by WADA
- Prescribability
- Available in Russia as dietary supplement; not approved in USA/EU
- Availability
- Not available through conventional pharmacies in the USA or EU.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(2)
- 2003-2004Clinical study conducted at St. Petersburg Institute (Oct 2003 - Jan 2004)
- 2000sCommercialized as Cytomaxes dietary supplement in Russia
Sources & FAQs
Research sources(1)
Frequently asked questions(3)
What liver conditions can Svetinorm be used for?
Svetinorm has been studied in chronic persisting hepatitis and post-chemotherapy liver recovery. It is marketed for chronic liver conditions, detoxification support, chronic intoxication, and age-related liver function decline.
How does Svetinorm differ from traditional liver supplements like milk thistle?
Svetinorm uses organ-specific peptides that are theorized to directly regulate hepatocyte metabolism through peptide-DNA interactions, rather than providing antioxidant or anti-inflammatory botanical compounds. The mechanisms are different.
How long do the effects of Svetinorm last?
According to Khavinson bioregulator theory, effects accumulate during treatment and persist for 3-6 months.